JW Pharmaceutical has acquired a 25% stake in Argonaut Therapeutics through a $2.6m investment.

This move makes JW Pharmaceutical the second biggest shareholder of Argonaut after Oxford Sciences Innovation.

Argonaut is developing protein arginine N-methyltransferase 5 (PRMT5) inhibitors as a targeted anticancer agent, which is said to have high selectivity compared with currently available drugs in the market.

The investment will be utilised to develop the PRMT5 inhibitors as a potential treatment for brain, pancreatic and metastatic gastric cancer.

JW Pharmaceutical is based in South Korea, while Argonaut is a UK-based start-up company of the University of Oxford that focuses on the development of next-generation oncology medicine.

Lonza has acquired a majority stake in Octane Biotech.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This stake will allow the chemicals and biotechnology company to further develop the Cocoon™ system, a patient-scale, automated cell therapy manufacturing solution that is the result of a three-year collaboration between the two companies.

“MC Healthcare plans to support business development for services platform Caresyntax by acquiring a minority stake in the firm.”

The acquisition will help Lonza meet growing needs for scalable autologous manufacturing.

The company also along gains the rights to acquire complete ownership of Octane Biotech in the future.

Based in Switzerland, Lonza is a biotechnology company, while Octane Biotech is based in Canada.

Karo Intressenter has made a public cash offer to Karo Pharma Aktiebolag’s shareholders for the acquisition of company shares.

Based in Sweden, Karo Intressenter is a subsidiary of EQT VIII, which is a closed private equity fund owned by EQT. Karo Pharma is a healthcare company that is also based in Sweden.

MC Healthcare plans to support business development for services platform Caresyntax by acquiring a minority stake in the firm.

The Canadian hospital solutions manufacturing company intends to develop Caresyntax’s internet-of-things (IoT), automation and other analytics solutions for care applications.

The solutions will also provide high-quality medical treatment and assistance in hospital operations.

Caresyntax is a surgical technology and services provider based in the US.